Molecular Formula | C14H20N2 |
Molar Mass | 216.32 |
Density | 1.07±0.1 g/cm3(Predicted) |
Boling Point | 347.4±42.0 °C(Predicted) |
Solubility | Soluble in DMSO |
Appearance | powder |
Color | white to beige |
pKa | 10.14±0.10(Predicted) |
Storage Condition | 2-8°C |
Use | GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B). |
In vitro study | GSK-LSD1 induces gene expression changes in cancer cell lines with average EC50 of < 5 nM and inhibits cancer cell line growth with average EC50 of < 5 nM. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.457 ml | 17.287 ml | 34.573 ml |
5 mM | 0.691 ml | 3.457 ml | 6.915 ml |
10 mM | 0.346 ml | 1.729 ml | 3.457 ml |
5 mM | 0.069 ml | 0.346 ml | 0.691 ml |
biological activity | GSK-LSD1 2HCl is an irreversible selective LSD1 inhibitor with an IC50 of 16 nM, the selectivity was more than 1000-fold higher than that of other closely related FAD available enzymes (I. E., LSD2,MAO-A,MAO-B). |